To characterize early SEMA responses, we measured serum concentrations of SEMA3A, 3F, 4D, 5A, and 7A at hospital admission (day 1) and on day 5 in patients with and without MASLD (Figure 3 and Supplementary Table S7). The gene discussed is SEMA3A; the disease is metabolic dysfunction-associated steatotic liver disease.